Cipla — While COVID scope continues, watch out for FY23 Trading Calls - Equity F&O May 17, 2021Recommendations Just when it seemed that Covid tailwinds are waning for Cipla, the drug maker has repositioned itself for the opportunities emerging from the second wave of the pandemic Anubhav Sahu
